Levi & Korsinsky notifies investors that it has commenced an investigation into AN2 Therapeutics, Inc. (NASDAQ: ANTX) concerning potential violations of the federal securities laws.
Before the market open on February 12, 2024, AN2 Therapeutics announced a pause in Phase 3 enrollment in its seamless Phase 2/3 clinical trial (EBO-301) evaluating epetraborole in treatment-refractory MAC lung disease, pending further data review. Following this news, shares of AN2 Therapeutics stock over 73% in premarket trading.
If you suffered a loss on your AN2 Therapeutics securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





